Download PDF
CC BY-NC-ND 4.0 · Int Arch Otorhinolaryngol 2020; 24(01): e73-e79
DOI: 10.1055/s-0039-1692406
Original Research
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

The Difference in Thyroid Stimulating Hormone Levels between Differentiated Carcinoma and Benign Enlargement

Bambang Udji Djoko Rianto 
1   Ear Nose Throat Head and Head Neck Surgery Department, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito GH Yogyakarta, Indonesia
,
Anton Sony Wibowo
1   Ear Nose Throat Head and Head Neck Surgery Department, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito GH Yogyakarta, Indonesia
,
Camelia Herdini
1   Ear Nose Throat Head and Head Neck Surgery Department, Faculty of Medicine, Universitas Gadjah Mada/Dr. Sardjito GH Yogyakarta, Indonesia
› Author Affiliations
Further Information

Publication History

26 March 2018

08 May 2019

Publication Date:
04 November 2019 (online)

   Permissions and Reprints

Abstract

Introduction Papillary and follicular thyroid carcinoma are common head and neck cancers. This cancer expresses a thyroid stimulating hormone (TSH) receptor that plays a role as a cancer stimulant substance. This hormone has a diagnostic value in the management of thyroid carcinoma.

Objective The present study aimed to determine the difference in TSH levels between differentiated thyroid carcinoma and benign thyroid enlargement.

Methods The present research design was a case-control study. The subjects were patients with thyroid enlargement who underwent thyroidectomies at the Dr. Sardjito General Hospital, Yogyakarta, Indonesia. Thyroid stimulating hormone levels were measured before the thyroidectomies. The inclusion criteria for the case group were: 1) differentiated thyroid carcinoma, and 2) complete data; while the inclusion criteria for the control group were: 1) benign thyroid enlargement, and 2) complete data. The exclusion criteria for both groups were: 1) patients suffering from thyroid hormone disorders requiring therapy before thyroidectomy surgery, 2) patients receiving thyroid suppression therapy before the thyroidectomy was performed, and 3) patients suffering from severe chronic diseases such as renal insufficiency, and severe liver disease.

Results There were 40 post-thyroidectomy case group patients and 40 post-thyroidectomy control group patients. There were statistically significant differences in TSH levels between the groups with differentiated thyroid carcinoma and benign thyroid enlargement (p = 0.001; odds ratio [OR] = 8.42; 95% confidence interval [CI]: 3.19–36.50).

Conclusion Based on these results, it can be concluded that there were significant differences in TSH levels between the groups with differentiated thyroid carcinoma and benign thyroid enlargement.

Keywords

thyroid stimulating hormone - thyroid adenoma - thyroid carcinoma - thyrotropin - thyroid neoplasms
 

  • References

  • 1 Cinamon U, Levy D, Marom T. Is primary hyperparathyroidism a risk factor for papillary thyroid cancer? An exemplar study and literature review. Int Arch Otorhinolaryngol 2015; 19 (01) 42-45
    PubMedGoogle Scholar
  • 2 Haugen BR, Alexander EK, Bible KC. , et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016; 26 (01) 1-133
    CrossrefPubMedGoogle Scholar
  • 3 Polyzos SA, Kita M, Efstathiadou Z. , et al. Serum thyrotropin concentration as a biochemical predictor of thyroid malignancy in patients presenting with thyroid nodules. J Cancer Res Clin Oncol 2008; 134 (09) 953-960
    CrossrefPubMedGoogle Scholar
  • 4 Tuncel M. Thyroid stimulating hormone receptor. Mol Imaging Radionucl Ther 2017; 26 (Suppl. 01) 87-91
    PubMedGoogle Scholar
  • 5 Khan MS, Pandith AA, Masoodi SR, Wani KA, Ul Hussain M, Mudassar S. Epigenetic silencing of TSHR gene in thyroid cancer patients in relation to their BRAF V600E mutation status. Endocrine 2014; 47 (02) 449-455
    CrossrefPubMedGoogle Scholar
  • 6 Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012; 97 (04) 1134-1145
    CrossrefPubMedGoogle Scholar
  • 7 Ramli NSF, Mat Junit S, Leong NK, Razali N, Jayapalan JJ, Abdul Aziz A. Analyses of antioxidant status and nucleotide alterations in genes encoding antioxidant enzymes in patients with benign and malignant thyroid disorders. PeerJ 2017; 5: e3365
    CrossrefPubMedGoogle Scholar
  • 8 Dirikoç A, Fakı S, Başer H. , et al. Thyroid malignancy risk in different clinical thyroid diseases. Turk J Med Sci 2017; 47 (05) 1509-1519
    CrossrefPubMedGoogle Scholar
  • 9 Williams D. Thyroid growth and cancer. Eur Thyroid J 2015; 4 (03) 164-173
    CrossrefPubMedGoogle Scholar
  • 10 Sulaieva O, Chernenko O. Correlations between TSH level and morphological features of thyroid tumours. P2–03–82. Eur Thyroid J 2017; 6 (Suppl. 01) 23-118
    CrossrefGoogle Scholar
  • 11 Podda M, Saba A, Porru F, Reccia I, Pisanu A. Follicular thyroid carcinoma: differences in clinical relevance between minimally invasive and widely invasive tumors. World J Surg Oncol 2015; 13 (193) 193
    CrossrefPubMedGoogle Scholar
  • 12 Carney HC, Ward CR, Bailey SJ. , et al. 2016 AAFP Guidelines for the Management of Feline Hyperthyroidism. J Feline Med Surg 2016; 18 (05) 400-416
    CrossrefPubMedGoogle Scholar
  • 13 Golbert L, de Cristo AP, Faccin CS. , et al. Serum TSH levels as a predictor of malignancy in thyroid nodules: A prospective study. PLoS One 2017; 12 (11) e0188123
    CrossrefPubMedGoogle Scholar
  • 14 Le KT, Sawicki MP, Wang MB, Hershman JM, Leung AM. High prevalence of agent orange exposure among thyroid cancer patients in the national VA healthcare system. Endocr Pract 2016; 22 (06) 699-702
    CrossrefPubMedGoogle Scholar
  • 15 Haymart MR, Repplinger DJ, Leverson GE. , et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 2008; 93 (03) 809-814
    CrossrefPubMedGoogle Scholar
  • 16 Khan MA, Malik N, Khan KH, Shahzad MF. Association of preoperative serum thyroid-stimulating hormone levels with thyroid cancer in patients with nodular thyroid disease. World J Nucl Med 2017; 16 (03) 202-205
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Pourhoseingholi MA, Vahedi M, Rahimzadeh M. Sample size calculation in medical studies. Gastroenterol Hepatol Bed Bench 2013; 6 (01) 14-17
    PubMedGoogle Scholar
  • 18 Ma Y, Zhang X, Wang Y. Reactivity of thyroid papillary carcinoma cells to thyroid stimulating hormone-dominated endocrine therapy. Oncol Lett 2017; 14 (06) 7405-7409
    PubMedGoogle Scholar
  • 19 Lee I-S, Hsieh A-T, Lee T-W, Lee T-I, Chien Y-M. The association of thyrotropin and autoimmune thyroid disease in developing papillary thyroid cancer. Int J Endocrinol 2017; •••: 1-8
    Google Scholar
  • 20 Gill KS, Tassone P, Hamilton J. , et al. Thyroid cancer metabolism: a review. J Thyroid Disord Ther 2016; 5 (01) 1-7
    Google Scholar
  • 21 Mussa A, De Andrea M, Motta M, Mormile A, Palestini N, Corrias A. Predictors of malignancy in children with thyroid nodules. J Pediatr 2015; 167 (04) 886-892.e1
    CrossrefPubMedGoogle Scholar
  • 22 Huang H, Rusiecki J, Zhao N. , et al. Thyroid-stimulating hormone, thyroid hormones, and risk of papillary thyroid cancer: a nested case–control study. Cancer Epidemiol Biomarkers Prev 2017; 26 (08) 1209-1218
    CrossrefPubMedGoogle Scholar
  • 23 Moon SS, Lee YS, Lee IK, Kim JG. Serum thyrotropin as a risk factor for thyroid malignancy in euthyroid subjects with thyroid micronodule. Head Neck 2012; 34 (07) 949-952
    CrossrefPubMedGoogle Scholar
  • 24 Cooper DS, Doherty GM, Haugen BR. , et al; American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006; 16 (02) 109-142
    CrossrefPubMedGoogle Scholar
  • 25 Tuttle RM, Ball DW, Byrd D. , et al; National Comprehensive Cancer Network. Thyroid carcinoma. J Natl Compr Canc Netw 2010; 8 (11) 1228-1274
    CrossrefPubMed
  • 26 Kim YJ, Lee KA, Park TS, Baek HS, Jin HY. Multiple metastasis of follicular variant of papillary thyroid carcinoma coexistent with malignant melanoma. Korean J Intern Med (Korean Assoc Intern Med) 2018; 33 (03) 634-637
    CrossrefPubMedGoogle Scholar
  • 27 Soh EY, Sobhi SA, Wong MG. , et al. Thyroid-stimulating hormone promotes the secretion of vascular endothelial growth factor in thyroid cancer cell lines. Surgery 1996; 120 (06) 944-947
    CrossrefPubMedGoogle Scholar
  • 28 Boelaert K. The association between serum TSH concentration and thyroid cancer. Endocr Relat Cancer 2009; 16 (04) 1065-1072
    CrossrefPubMedGoogle Scholar
  • 29 Pujol P, Daures J-P, Nsakala N, Baldet L, Bringer J, Jaffiol C. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996; 81 (12) 4318-4323
    PubMedGoogle Scholar
  • 30 Beasley MJ. Lymphoma of the thyroid and head and neck. Clin Oncol (R Coll Radiol) 2012; 24 (05) 345-351
    CrossrefPubMedGoogle Scholar
  • 31 Gul K, Ozdemir D, Dirikoc A. , et al. Are endogenously lower serum thyroid hormones new predictors for thyroid malignancy in addition to higher serum thyrotropin?. Endocrine 2010; 37 (02) 253-260
    CrossrefPubMedGoogle Scholar
  • 32 Tuttle RM, Lemar H, Burch HB. Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. Thyroid 1998; 8 (05) 377-383
    CrossrefPubMedGoogle Scholar
  • 33 Lin Jen-Der, Lin Shu-Fu, Chen Szu-Tah, Hsueh C, Li Chia-Lin, Chao Tzu-Chieh. Long-term follow-up of papillary and follicular thyroid carcinomas with bone metastasis. PLoS One 2017; 9: 1-11
    Google Scholar
  • 34 Lamartina L, Grani G, Durante C, Filetti S. Recent advances in managing differentiated thyroid cancer. F1000Res.ecollection 2018; 7: 1-10
    Google Scholar
  • 35 Deirdre K, Catherine MK. Clinical overview of thyroid cancer and recent advances in treatment. J Oncol Med & Pract. 2016; 1 (02) 1-6
    Google Scholar
  • 36 Dean DS, Hay ID. Prognostic indicators in differentiated thyroid carcinoma. Cancer Contr 2000; 7 (03) 229-239
    Google Scholar
  • 37 Mitchell AL, Gandhi A, Scott-Coombes D, Perros P. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines. J Laryngol Otol 2016; 130 (S2): S150-S160
    PubMedGoogle Scholar
  • 38 Frates MC, Benson CB, Doubilet PM. , et al. Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. J Clin Endocrinol Metab 2006; 91 (09) 3411-3417
    CrossrefPubMedGoogle Scholar